(IN BRIEF) Scientists at the Institute of Cancer Research in London are contributing to an international clinical trial evaluating THEO-260, an experimental oncolytic immunotherapy designed to treat platinum-resistant ovarian cancer. The trial, known as OCTOPOD-IV, is being supported by €8 … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alan Melcher, cancer associated fibroblasts CAF, Cancer Center Clínica Universidad de Navarra, cancer immunotherapy development, Catalan Institute of Oncology, Horizon Europe funding, ICR cancer research, Institute of Cancer Research Joins International Trial of Novel Oncolytic Immunotherapy for Platinum-Resistant Ovarian Cancer, Institute of Cancer Research London, International Cancer Research Collaboration Advances Clinical Study of THEO-260 Immunotherapy for Hard-to-Treat Ovarian Tumours, Margaret Duffy, OCTOPOD IV clinical trial, oncolytic virus therapy, ovarian cancer research, platinum resistant ovarian cancer, Princess Margaret Cancer Centre, THEO 260 oncolytic immunotherapy, Theolytics biotechnology, translational cancer research, tumour microenvironment research
(IN BRIEF) Researchers at The Institute of Cancer Research, London have created a next-generation PROTAC degrader that successfully eliminates the cancer-related protein Aurora A while overcoming the hook effect that has limited earlier degraders. The new molecule, CCT400028, demonstrates improved … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged alisertib, Aurora A kinase, Cancer Research UK, cancer therapeutics, CCT400028, chemical probes, Children’s Brain Tumour Centre of Excellence CBTCE, Gary Newton, glioma, hook effect, Institute of Cancer Research Develops Advanced Aurora A PROTAC Degrader That Overcomes Hook Effect and Improves Stability, Institute of Cancer Research London, Journal of Medicinal Chemistry, leukaemia, Lindsay Evans, Neuroblastoma, New Aurora A Degrader from Institute of Cancer Research Demonstrates Improved Selectivity and Reliability in Cancer Studies, paediatric cancers, Paul Workman, PROTAC, protein degradation technology, targeted protein degradation, University of Kiel
(IN BRIEF) The Institute of Cancer Research, London, has led the development of OPTIMISE-ROR, the first structured guidance outlining how patient-reported outcomes should be used in early-stage cancer dose-finding trials. Published in the Journal of Clinical Oncology, the recommendations provide … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Research UK, Christina Yap, clinical trials methodology, dose-finding studies, early-stage cancer trials, Emily Alger, Experimental Cancer Medicine Centre, ICR, Institute of Cancer Research Develops First Foundational Framework for Patient-Reported Outcomes in Early Oncology Trials, Institute of Cancer Research London, International Study Led by ICR Strengthens Role of Patient Experience in Early-Phase Cancer Drug Development, Journal of Clinical Oncology, oncology research, OPTIMISE-ROR, patient-reported outcomes, PROs
(IN BRIEF) The Institute of Cancer Research has welcomed NICE’s recommendation of talazoparib in combination with enzalutamide for adults with metastatic prostate cancer, providing a new treatment option for around 2,400 patients in England who are unsuitable for chemotherapy. Backed … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged BRCA mutations, DNA repair gene mutations, enzalutamide, Institute of Cancer Research London, metastatic prostate cancer, NICE recommendation, NICE Recommendation of Talazoparib Marks New Treatment Option for Advanced Prostate Cancer, PARP inhibitors, prostate cancer treatment, Royal Marsden NHS Foundation Trust, TALAPRO trials, talazoparib, Talzenna, targeted cancer therapy
(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged abiraterone, AKT inhibitor, biomarkers, clinical trial, genetic markers, Institute of Cancer Research London, ipatasertib, IPATential150 trial, metastatic castration-resistant prostate cancer mCRPC, overall survival, personalized medicine, PIK3CA/AKT1/PTEN pathway, Professor Johann de Bono, PTEN gene, Roche, sequencing techniques, synthetic lethality, targeted therapy, UK patients
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?